A
What happened
The Bombay High Court ruled against RB Remedies and Origin Formulations, restraining their sale of cough syrup branded 'CEFDON', as it was visually and phonetically confusable with Blue Cross Laboratories' registered trademark 'CEDON'. The dispute originated from 2014 when Blue Cross issued a cease-and-desist notice. Despite evidence of significant sales growth for 'CEFDON', the court emphasized bad faith, consumer deception risk, and public health safety, awarding ₹10 lakh costs to Blue Cross payable within eight weeks, with interest on delay.
★
Key insights
-
1
Judicial emphasis on trademark protection in pharmaceuticals: The ruling highlights courts' focus on preventing deceptive marks in health-related products to safeguard consumer trust and public safety.
-
2
Link between bad faith use and deterrence through cost penalties: Imposing substantial costs signals judicial intolerance for dishonest trademark practices, potentially deterring similar infringements.
Takeaways
The Bombay High Court's decision enforces stringent trademark standards in pharmaceuticals, underscoring legal protection against deceptive branding that could harm consumers.